Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - estradiolum, norethisteroni acetas - cerotti transdermici - estradiolum 0,60 mg per estradiolum hemihydricum 0.62 mg, norethisteroni acetas 2.7 mg, silicone adesivo, adesivo acrilico, povidonum k 30, acido oleicum, dipropylenglycolum, trägermaterial: la preparazione per il 9 cm2, con la liberazione di 50 µg e 140 µg/24 h. - estrogeno-progestinici terapia sostitutiva dopo la menopausa - synthetika

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - estradiolum, norethisteroni acetas - cerotti transdermici - estradiolum 0.496 mg per estradiolum hemihydricum 0.512 mg, norethisteroni acetas 4.8 mg, silicone adesivo, adesivo acrilico, povidonum k 30, acido oleicum, dipropylenglycolum, trägermaterial: la preparazione per il 16 cm2, con la liberazione di 50 µg e 250 µg/24 h. - estrogeno-progestinici terapia sostitutiva dopo la menopausa - synthetika

Unia Europejska - włoski - EMA (European Medicines Agency)

leo pharma a/s - tacrolimus - dermatite, atopica - altri preparati dermatologici - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. che si verificano quattro o più volte all'anno), che hanno avuto una prima risposta a un massimo di sei settimane, il trattamento di tacrolimus unguento due volte al giorno (lesioni cancellato, quasi cancellato o moderatamente influenzato).

Włochy - włoski - AIFA (Agenzia Italiana del Farmaco)

wyeth lederle s.r.l. - demeclociclina - demeclociclina

Unia Europejska - włoski - EMA (European Medicines Agency)

leo pharma a/s - tralokinumab - dermatite, atopica - altri preparati dermatologici - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Unia Europejska - włoski - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatite, atopica - altri preparati dermatologici - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Unia Europejska - włoski - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatite, atopica - altri preparati dermatologici - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

Unia Europejska - włoski - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artrite, reumatoide - immunosoppressori - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant può essere usato in monoterapia o in combinazione con metotrexato. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Unia Europejska - włoski - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrite, reumatoide - immunosoppressori - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Unia Europejska - włoski - EMA (European Medicines Agency)

zoetis belgium sa - oclacitinib maleato - agenti per dermatiti, esclusi i corticosteroidi - cani - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.